CIK 0001650664 · Non-accelerated filer<br>Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464097528
- Phone
- 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,092
- in 3 filings, $19K under 10b5-1 plans
Net −$19,092. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-08 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +275,100 | 275,100 | ||
| 2025-03-08 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2025-03-08 | O'Neill Gilmore Neil CEO | Grant or award · Stock Option (right to buy) | +828,000 | 828,000 | ||
| 2025-03-08 | O'Neill Gilmore Neil CEO | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2025-03-08 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) | +275,100 | 275,100 | ||
| 2025-03-08 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2025-03-04 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −4,109 | $1.71 | $7K | 112,720 |
| 2025-03-04 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −16,632 | $1.71 | $28K | 295,474 |
| 2025-03-04 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −2,891 | $1.71 | $5K | 70,245 |
| 2024-12-03 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −1,618 | $2.08 | $3K | 312,106 |
| 2024-12-03 | Mei Baisong EVP, CHIEF MEDICAL OFFICER | Sale 10b5-1 | −541 | $2.08 | $1K | 133,354 |
| 2024-09-04 | Mei Baisong EVP, CHIEF MEDICAL OFFICER | Sale 10b5-1 | −518 | $3.42 | $2K | 133,895 |
| 2024-09-04 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −1,555 | $3.42 | $5K | 313,724 |
| 2024-07-25 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −11,886 | $5.42 | $64K | 73,136 |
| 2024-07-19 | Mei Baisong EVP, CHIEF MEDICAL OFFICER | Sale 10b5-1 | −6,619 | $5.21 | $34K | 134,413 |
| 2024-06-04 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −12,191 | $5.50 | $67K | 315,279 |
| 2024-06-04 | Mei Baisong EVP, CHIEF MEDICAL OFFICER | Sale 10b5-1 | −511 | $5.50 | $3K | 141,032 |
| 2024-05-30 | Scadden David Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-30 | Hopfield Jessica Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-30 | Chatterjee Meeta Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 |
Page 3 of 15 · 283 trades